Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Kinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in Leishmania.

de Mendonça SC, Cysne-Finkelstein L, Matos DC.

Front Immunol. 2015 Oct 13;6:524. doi: 10.3389/fimmu.2015.00524. eCollection 2015. Review.

2.

Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responses.

Kansal S, Tandon R, Verma A, Misra P, Choudhary AK, Verma R, Verma PR, Dube A, Mishra PR.

Br J Pharmacol. 2014 Sep;171(17):4038-50. doi: 10.1111/bph.12754. Epub 2014 Jul 25.

3.

Therapeutic options for visceral leishmaniasis.

Monge-Maillo B, López-Vélez R.

Drugs. 2013 Nov;73(17):1863-88. doi: 10.1007/s40265-013-0133-0. Review.

4.

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.

Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P.

PLoS Negl Trop Dis. 2012;6(5):e1657. doi: 10.1371/journal.pntd.0001657. Epub 2012 May 22.

5.

rK39 antigen for the diagnosis of visceral leishmaniasis by using human saliva.

Vaish M, Singh OP, Chakravarty J, Sundar S.

Am J Trop Med Hyg. 2012 Apr;86(4):598-600. doi: 10.4269/ajtmh.2012.11-0127.

6.

In vitro and in vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis.

Taylor VM, Cedeño DL, Muñoz DL, Jones MA, Lash TD, Young AM, Constantino MH, Esposito N, Vélez ID, Robledo SM.

Antimicrob Agents Chemother. 2011 Oct;55(10):4755-64. doi: 10.1128/AAC.00671-11. Epub 2011 Jul 25.

7.

Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors.

Wang SF, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquère K, Badoual C, Damotte D, Validire P, Maubec E, Delongchamps NB, Cazes A, Gibault L, Garcette M, Dieu-Nosjean MC, Zerbib M, Avril MF, Prévost-Blondel A, Randriamampita C, Trautmann A, Bercovici N.

PLoS One. 2011 Mar 7;6(3):e17621. doi: 10.1371/journal.pone.0017621.

8.

Noninvasive molecular diagnosis of human visceral leishmaniasis.

Vaish M, Mehrotra S, Chakravarty J, Sundar S.

J Clin Microbiol. 2011 May;49(5):2003-5. doi: 10.1128/JCM.00130-11. Epub 2011 Mar 9.

9.

IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.

Ansari NA, Kumar R, Gautam S, Nylén S, Singh OP, Sundar S, Sacks D.

J Immunol. 2011 Apr 1;186(7):3977-85. doi: 10.4049/jimmunol.1003588. Epub 2011 Feb 28.

10.

Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride.

Thakur CP, Kumar A, Mitra DK, Roy A, Sinha AK, Ranjan A.

Am J Trop Med Hyg. 2010 Nov;83(5):1040-3. doi: 10.4269/ajtmh.2010.10-0255.

11.

Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.

Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, Parreño F, Pandey K.

Am J Trop Med Hyg. 2010 Aug;83(2):357-64. doi: 10.4269/ajtmh.2010.10-0156.

12.

Uptake of biodegradable gel-assisted LBL nanomatrix by Leishmania donovani-infected macrophages.

Gupta GK, Kansal S, Misra P, Dube A, Mishra PR.

AAPS PharmSciTech. 2009;10(4):1343-7. doi: 10.1208/s12249-009-9334-y. Epub 2009 Nov 11.

13.

Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions.

Liu D, Kebaier C, Pakpour N, Capul AA, Beverley SM, Scott P, Uzonna JE.

Infect Immun. 2009 Aug;77(8):3272-83. doi: 10.1128/IAI.01447-08. Epub 2009 Jun 1.

14.

Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis.

Schriefer A, Wilson ME, Carvalho EM.

Curr Opin Infect Dis. 2008 Oct;21(5):483-8. doi: 10.1097/QCO.0b013e32830d0ee8. Review.

15.

Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis.

Nylén S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D.

J Exp Med. 2007 Apr 16;204(4):805-17. Epub 2007 Mar 26.

16.

Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.

Sánchez-Brunete JA, Dea MA, Rama S, Bolás F, Alunda JM, Raposo R, Méndez MT, Torrado-Santiago S, Torrado JJ.

Antimicrob Agents Chemother. 2004 Sep;48(9):3246-52.

17.

Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.

Maes L, Germonprez N, Quirijnen L, Van Puyvelde L, Cos P, Vanden Berghe D.

Antimicrob Agents Chemother. 2004 Jun;48(6):2056-60.

Supplemental Content

Support Center